Glucose and other bioincompatible factors of conventional peritoneal dialysis solutions may damage the peritoneal membrane. The aim of our study was to investigate whether replacement of glucose with icodextrin (ID) or amino acids (AA) affects inflammatory parameters or cancer antigen 125 (CA125).
Design
Either ID or AA was used, in random order, in one daily exchange during an 8-week period. After the first study period, the patients entered a washout period and then switched to the other study solution for an 8-week period. C-reactive protein (CRP) was measured in serum, and CA125, tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), soluble intercellular adhesion molecule-1 (sICAM-1), and hyaluronan (HA) were measured in the overnight dwell dialysates at the beginning and end of the study periods.
Setting
A university hospital.
Patients
22 patients with duration on peritoneal dialysis of 1.5 – 6.3 months.
Main Outcome Measures
Levels of serum CRP and dialysate CA125, IL-6, HA, and sICAM-1 during use of ID and AA were compared to levels during use of glucose-only-based solutions.
Results
CRP increased significantly during use of ID. CA125 increased significantly during 8 weeks’ use of AA, from 22.8 (5.4 – 89.0) to 42.9 (7.1 – 92.9) kU/L (p = 0.007). IL-6 increased during 8 weeks’ use of AA, from 22.0 (9.0 – 108.0) to 36.5 (14.0 – 93.0) ng/L (p = 0.002) and ID, from 25.5 (8.0 – 82.0) to 40.0 (12.0 – 118.0) ng/L (p = 0.008). TNF-α also increased significantly during use of ID, but showed no significant changes during use of AA.
Conclusions
The use of glucose-free solutions, especially AA, may lead to preservation of mesothelial cell mass and host defense. However, activation of systemic and peritoneal inflammation may appear during the use of ID and to a lesser extent during use of AA.
MisraM., AshworthJ., ReaveleyD.A., MullerB., BrownE.A.Nutritional effects of amino acid dialysate (Nutrineal) in CAPD patients.Adv Perit Dial1996; 12: 311–14.
2.
JonesM.R., GehrT.W., BurkartJ.M., HamburgerR.J., KrausA.P., PirainoB.M.Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution.Perit Dial Int1998; 18: 210–16.
3.
MisraM., ReaveleyD.A., AshworthJ., MullerB., SeedM., BrownE.A.Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis.Perit Dial Int1997; 17: 279–86.
4.
BrulezH.F., van GuldenerC., DonkerA.J., ter WeeP.M.The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass.Nephrol Dial Transplant1999; 14: 154–9.
5.
YoungG.A., DibbleJ.B., HobsonS.M., TompkinsL., GibsonJ., TurneyJ.H.The use of an amino-acid-based CAPD fluid over 12 weeks.Nephrol Dial Transplant1989; 4: 285–92.
6.
PeersE., GokalR.Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume.Artif Organs1998; 22: 8–12.
7.
CookerL.A., ChooC.G., LuneburgP., LamelaJ., HolmesC.J.Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro.Adv Perit Dial1999; 15: 17–20.
8.
BarreD.E., ChenC., CookerL., MoberlyJ.B.Decreased in vitro formation of AGEs with Extraneal solution compared to dextrose-containing peritoneal dialysis solutions.Adv Perit Dial1999; 15: 12–16.
9.
PosthumaN., ter WeeP.M., NiessenH., DonkerA.J., VerbrughH.A., SchalkwijkC.G.Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin.Perit Dial Int2001; 21: 43–51.
10.
SiscaS., MaggioreU.Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients.Perit Dial Int2002; 22: 727–9.
11.
BredieS., BoschF., DemackerP., StalenhoefA., van LeusenR.Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism.Perit Dial Int2001; 21: 275–81.
12.
TeppoA-M, MetsärinneK., FyhrquistF.Radioimmunoassay of interleukin-6 in plasma.Clin Chem1991; 37: 1691–5.
13.
TeppoA-M, MauryC.Radioimmunoassay of tumour necrosis factor-alfa in serum.Clin Chem1987; 33: 2024–7.
14.
TeppoA-M, von WillebrandE., HonkanenE., AhonenJ., Grönhagen-RiskaC.Soluble intercellular adhesion molecule-1 (sICAM-1) after kidney transplantation: The origin and role of urinary sICAM-1?Transplantation2001; 71: 1113–19.
VisserC.E., Brouwer-SteenbergenJ.J., BetjesM.G., KoomenG.C., BeelenR.H., KredietR.T.Cancer antigen 125: A bulk marker for the mesothelial mass in stable peritoneal dialysis patients.Nephrol Dial Transplant1995; 10: 64–9.
17.
HaraldssonB.Assessing the peritoneal dialysis capacities of individual patients.Kidney Int1995; 47: 1187–98.
18.
TeppoA-M, TörnrothT., HonkanenE., Gronhagen-RiskaC.Elevated serum C-reactive protein associates with deterioration of renal function in transplant recipients.Clin Nephrol2003; 60: 248–56.
19.
BlakeG., RifaiN., BuringJ., RidkerP.Blood pressure, C-reactive protein, and risk of future cardiovascular events.Circulation2003; 108: 2993–9.
20.
WangA., WooJ., LamC., WangM., SeaM.M., LuiS.F.Is a single time point C- reactive protein predictive of outcome in peritoneal dialysis patients?Perit Dial Int2003; 23: 174–83.
21.
DuclouxD., Bresson-VautrinC., KribsM., AbdelfatahA., ChalopinJ.M.C-reactive protein and cardiovascular disease in peritoneal dialysis patients.Kidney Int2002; 62: 1417–22.
22.
StenvinkelP., HeimburgerO., LindholmB., KaysenG.A., BergströmJ.Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome).Nephrol Dial Transplant2000; 15: 953–60.
VisserM., BeuterM., McQuillanG.M., WenerM.H., HarrisT.B.Elevated C-reactive protein levels in over-weight and obese adults.JAMA1999; 282: 2131–5.
25.
CappelliG., BandianiG., CancariniG.C., FerianiM., Dell'AquilaR., SaffiotiS.Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag.Adv Perit Dial1999; 15: 238–42.
26.
HaH., ChaM.K., ChoiH.N., LeeH.B.Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells.Perit Dial Int2002; 22: 171–7.
27.
BajoM.A., SelgasR., CastroM.A., del PesoG., DiazC., Sanches-TomeroJ.A.Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo.Perit Dial Int2000; 20: 742–7.
28.
LiberekT., TopleyN., MistryC.D., ColesG.A., MorganT., QuirkR.A.Cell function and viability in glucose polymer peritoneal dialysis fluids.Perit Dial Int1993; 13: 104–11.
29.
PlumJ., LordnejadM.R., GrabenseeB.Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes.Kidney Int1998; 54: 224–35.
30.
PosthumaN., VerbrughH.A., DonkerA.J., van DorpW., DekkerH.A., PeersE.M.Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years.Perit Dial Int2000; 20: 174–80.
31.
ParikovaA., ZweersM., StruijkD., KredietR.T.Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.Adv Perit Dial2003; 19: 180–90.
32.
GotloibL., WajsbrotV., ShostakA.Mesothelial dysplastic changes and lipid peroxidation induced by 7.5% icodextrin.Nephron2002; 92: 142–55.
33.
BrulezH.F., DekkerH.A., OeP.L., VerbeelenD., ter WeeP.M., VerbrughH.A.Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid.Nephron1996; 74: 26–32.
34.
ChanT.M., LeungJ.K., SunY., LaiK.N., TsangR.C., YungS.Different effects of amino acid-based and glucose-based dialysate from peritoneal dialysis patients on mesothelial cell ultrastructure and function.Nephrol Dial Transplant2003; 18: 1086–94.
35.
GarosiG., GaggiottiE., MonaciG., BrardiS., Di PaoloN.Biocompatibility of a peritoneal dialysis solution with amino acids: Histological evaluation in the rabbit.Perit Dial Int1998; 18: 610–19.
36.
ElsnerJ., SachM., KnopfH.P., NorgauerJ., KappA., SchollmeyerP.Synthesis and surface expression of ICAM-1 in polymorphonuclear neutrophilic leukocytes in normal subjects and during inflammatory disease.Immunobiology1995; 193: 456–64.
37.
MartikainenT.A., EkstrandA.V., TeppoA-M, HonkanenE.O., Grönhagen-RiskaC.Cytokines and other soluble factors in dialysate: Indicators of altered peritoneal function?Scand J Urol Nephrol2002; 36: 450–4.
